HLD-0915, a RIPTACT therapeutic, targets mCRPC by linking the androgen receptor with an effector protein, disrupting cancer cell functions. The phase 1/2 trial will evaluate HLD-0915's safety, ...
Add Yahoo as a preferred source to see more of our stories on Google. PARIS — Investment fund HLD has entered into exclusive talks with the founders of Jimmy Fairly and Experienced Capital to acquire ...
In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Halda Therapeutics (Halda) in a $3.05bn cash deal. The acquisition brings Halda's lead candidate, HLD-0915, a ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results